GUTSUIT GG

Lactobacillus rhamnosus GG (LGG) is the world's most extensively studied and clinically validated probiotic strain — with over 800 randomised controlled trials and a body of evidence that far exceeds any other probiotic organism. The GG designation identifies the specific Gorbach-Goldin strain, isolated in 1985 and commercially developed based on its unique combination of properties that distinguish it from other Lactobacillus strains.

LGG's mechanisms of action are multi-layered and well-characterised:

1. Colonisation Resistance: LGG adheres to human intestinal mucus and epithelium with exceptional tenacity — its fimbriae (pili) bind specifically to intestinal mucus glycoproteins, enabling transient but effective colonisation during a supplementation course. This adherence competitively excludes pathogenic bacteria (Salmonella, Rotavirus, C. difficile, E. coli) from mucosal attachment sites.

2. Mucus Layer Enhancement: LGG stimulates goblet cell MUC2 and MUC3 mucin gene expression, thickening the protective intestinal mucus layer that physically separates the epithelium from luminal bacteria and antigens.

3. Tight Junction Restoration: Through activation of the MAP kinase pathway, LGG upregulates occludin and claudin-3 expression in intestinal tight junctions, restoring barrier integrity disrupted by diarrhoeal pathogens, antibiotics, or inflammatory conditions.

4. Immune Modulation: LGG activates intestinal IgA production, stimulates Toll-like receptor signalling to increase innate mucosal immunity without triggering excessive pro-inflammatory responses, and modulates regulatory T-cell activity to reduce inappropriate immune activation.

5. Bacteriocin Production: LGG produces reuterin and other bacteriocins — antimicrobial peptides with direct killing activity against intestinal pathogens including C. difficile.

The drops format delivers LGG in an oil-suspension that protects the organism during gastric transit — LGG's natural acid tolerance is enhanced by the lipid vehicle.

LGG is the most evidence-based probiotic for paediatric conditions — with Level I RCT evidence in multiple acute indications that no other probiotic strain can match.

Acute Infectious Diarrhoea in Children (Primary — Highest Evidence Level): LGG is the only probiotic with consistent Level I evidence for reducing the duration of acute diarrhoea in children — Cochrane reviews confirm LGG reduces rotavirus diarrhoea duration by approximately 1 day (a clinically significant reduction in a condition lasting 5–7 days). This evidence specifically applies to LGG at sufficient doses, not to other Lactobacillus strains.

Antibiotic-Associated Diarrhoea (Highest Evidence Level): LGG has the strongest evidence of any probiotic for preventing antibiotic-associated diarrhoea — consistent across multiple RCTs and meta-analyses. Given alongside any antibiotic course in children, LGG significantly reduces diarrhoea incidence. Critically, LGG is resistant to amoxycillin and many other antibiotics — ensuring viability when co-administered.

C. difficile Infection Prevention: LGG supplementation during and after antibiotic therapy reduces the risk of C. difficile overgrowth — particularly relevant in hospitalised or recently hospitalised children.

Colic Reduction in Breastfed Infants: RCTs specifically in breastfed infants demonstrate LGG (at 10⁸ CFU/day) significantly reduces crying time in infantile colic compared to simethicone — through microbiome modulation and intestinal gas reduction.

Eczema Prevention: Prenatal and early postnatal LGG supplementation has the most consistent evidence of any probiotic for reducing atopic dermatitis risk in high-risk infants — a unique immunomodulatory indication beyond GI conditions.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.